Journal
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
Volume 77, Issue 8, Pages 1494-1502Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/gerona/glab172
Keywords
Aging; Bisphosphonates; DNA damage; Drosophila; Life span
Categories
Funding
- University of Sheffield PhD studentship award
Ask authors/readers for more resources
Increased longevity has not been accompanied by extended health span. Zoledronate, a drug used to prevent osteoporosis, has been found to extend lifespan, improve physical activity, and reduce the occurrence of intestinal disease and permeability. It enhances resistance to oxidative stress and reduces DNA damage accumulation. Zoledronate also interacts with molecules associated with increased longevity. Therefore, repurposing Zoledronate holds great promise for improving health span.
Over recent decades, increased longevity has not been paralleled by extended health span, resulting in more years spent with multiple diseases in older age. As such, interventions to improve health span are urgently required. Zoledronate (Zol) is a nitrogen-containing bisphosphonate, which inhibits the farnesyl pyrophosphate synthase enzyme, central to the mevalonate pathway. It is already used clinically to prevent fractures in osteoporotic patients, who have been reported to derive unexpected and unexplained survival benefits. Using Drosophila as a model we determined the effects of Zol on life span, parameters of health span (climbing ability and intestinal dysplasia), and the ability to confer resistance to oxidative stress using a combination of genetically manipulated Drosophila strains and Western blotting. Our study shows that Zol extended life span, improved climbing activity, and reduced intestinal epithelial dysplasia and permeability with age. Mechanistic studies showed that Zol conferred resistance to oxidative stress and reduced accumulation of X-ray-induced DNA damage via inhibition of farnesyl pyrophosphate synthase. Moreover, Zol was associated with inhibition of phosphorylated AKT in the mammalian traget of rapamycin pathway downstream of the mevalonate pathway and required dFOXO for its action, both molecules associated with increased longevity. Taken together, our work indicates that Zol, a drug already widely used to prevent osteoporosis and dosed only once a year, modulates important mechanisms of aging. Its repurposing holds great promise as a treatment to improve health span.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available